ABBVIE INC (1ABBV.MI) Stock Fundamental Analysis
Europe - BIT:1ABBV - US00287Y1091 - Common Stock
201 EUR
+0.5 (+0.25%)
Overall 1ABBV gets a fundamental rating of 5 out of 10. We evaluated 1ABBV against 79 industry peers in the Biotechnology industry. While 1ABBV is still in line with the averages on profitability rating, there are concerns on its financial health. 1ABBV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1ABBV was profitable.
In the past year 1ABBV had a positive cash flow from operations.
In the past 5 years 1ABBV has always been profitable.
In the past 5 years 1ABBV always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.71%, 1ABBV is in the better half of the industry, outperforming 77.22% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 13.81%, 1ABBV belongs to the top of the industry, outperforming 87.34% of the companies in the same industry.
1ABBV had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 15.27%.
The 3 year average ROIC (13.67%) for 1ABBV is below the current ROIC(13.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
Looking at the Profit Margin, with a value of 6.38%, 1ABBV belongs to the top of the industry, outperforming 81.01% of the companies in the same industry.
In the last couple of years the Profit Margin of 1ABBV has declined.
With an excellent Operating Margin value of 31.27%, 1ABBV belongs to the best of the industry, outperforming 87.34% of the companies in the same industry.
1ABBV's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 70.93%, 1ABBV is in the better half of the industry, outperforming 64.56% of the companies in the same industry.
1ABBV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1ABBV is still creating some value.
The number of shares outstanding for 1ABBV remains at a similar level compared to 1 year ago.
1ABBV has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 1ABBV is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.45 indicates that 1ABBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of 1ABBV (2.45) is better than 65.82% of its industry peers.
1ABBV has a debt to FCF ratio of 3.86. This is a good value and a sign of high solvency as 1ABBV would need 3.86 years to pay back of all of its debts.
1ABBV's Debt to FCF ratio of 3.86 is amongst the best of the industry. 1ABBV outperforms 81.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.45 |
ROIC/WACC1.52
WACC9.11%
2.3 Liquidity
1ABBV has a Current Ratio of 0.74. This is a bad value and indicates that 1ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
1ABBV's Current ratio of 0.74 is on the low side compared to the rest of the industry. 1ABBV is outperformed by 77.22% of its industry peers.
A Quick Ratio of 0.61 indicates that 1ABBV may have some problems paying its short term obligations.
1ABBV has a worse Quick ratio (0.61) than 78.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
1ABBV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
Looking at the last year, 1ABBV shows a small growth in Revenue. The Revenue has grown by 6.05% in the last year.
1ABBV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.11% yearly.
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
3.2 Future
1ABBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.59% yearly.
1ABBV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y21.19%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
EPS Next 5Y13.59%
Revenue Next Year8.21%
Revenue Next 2Y8.6%
Revenue Next 3Y8.22%
Revenue Next 5Y7.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.97, the valuation of 1ABBV can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 1ABBV indicates a rather cheap valuation: 1ABBV is cheaper than 82.28% of the companies listed in the same industry.
1ABBV's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.34.
A Price/Forward Earnings ratio of 15.98 indicates a correct valuation of 1ABBV.
Based on the Price/Forward Earnings ratio, 1ABBV is valued cheaper than 88.61% of the companies in the same industry.
1ABBV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.97 | ||
| Fwd PE | 15.98 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1ABBV indicates a somewhat cheap valuation: 1ABBV is cheaper than 78.48% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1ABBV indicates a rather cheap valuation: 1ABBV is cheaper than 83.54% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.52 | ||
| EV/EBITDA | 17.7 |
4.3 Compensation for Growth
1ABBV's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of 1ABBV may justify a higher PE ratio.
A more expensive valuation may be justified as 1ABBV's earnings are expected to grow with 16.82% in the coming years.
PEG (NY)1.04
PEG (5Y)8.75
EPS Next 2Y19.9%
EPS Next 3Y16.83%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.77%, 1ABBV has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 12.99, 1ABBV pays a better dividend. On top of this 1ABBV pays more dividend than 94.94% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, 1ABBV has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.77% |
5.2 History
On average, the dividend of 1ABBV grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
304.54% of the earnings are spent on dividend by 1ABBV. This is not a sustainable payout ratio.
1ABBV's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
BIT:1ABBV (10/13/2025, 7:00:00 PM)
201
+0.5 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap355.08B
Analysts79.46
Price Target197.82 (-1.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.77% |
Yearly Dividend5.32
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)4.76%
PT rev (3m)5.18%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)1.75%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.44%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.97 | ||
| Fwd PE | 15.98 | ||
| P/S | 7.04 | ||
| P/FCF | 22.52 | ||
| P/OCF | 21.3 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.7 |
EPS(TTM)9.15
EY4.55%
EPS(NY)12.58
Fwd EY6.26%
FCF(TTM)8.92
FCFY4.44%
OCF(TTM)9.44
OCFY4.69%
SpS28.54
BVpS-0.09
TBVpS-45.43
PEG (NY)1.04
PEG (5Y)8.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.45 |
F-Score6
WACC9.11%
ROIC/WACC1.52
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
EPS Next Y21.19%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
EPS Next 5Y13.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
Revenue Next Year8.21%
Revenue Next 2Y8.6%
Revenue Next 3Y8.22%
Revenue Next 5Y7.22%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%